var data={"title":"Pertuzumab: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pertuzumab: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/511750?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pertuzumab-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pertuzumab: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14471959\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cardiotoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Pertuzumab can result in subclinical and clinical cardiac failure manifesting as decreased left ventricular ejection fraction (LVEF) and congestive heart failure (CHF). Evaluate cardiac function prior to and during treatment. Discontinue pertuzumab treatment for a confirmed clinically significant decrease in left ventricular function.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pregnancy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Exposure to pertuzumab can result in embryo-fetal death and birth defects. Advise patients of these risks and the need for effective contraception.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14476879\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Perjeta</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21099907\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Perjeta</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14448325\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Anti-HER2;</li>\n      <li>\n        Antineoplastic Agent, Monoclonal Antibody</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472492\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;\">\n      <b>Note:</b> For pertuzumab, trastuzumab, and taxane combination regimens, pertuzumab and trastuzumab may be administered in any order; however, the taxane should be given after pertuzumab and trastuzumab. Pertuzumab (and trastuzumab) should be administered following completion of the anthracycline therapy in patients receiving anthracycline-based regimens. Observe patients for 30 to 60 minutes after each pertuzumab infusion and before subsequent infusions of trastuzumab or docetaxel.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Breast cancer, metastatic HER2+:</b> IV: 840 mg over 60 minutes followed by a maintenance dose of 420 mg over 30 to 60 minutes every 3 weeks until disease progression or unacceptable toxicity (in combination with trastuzumab and docetaxel) (Baselga 2012; Swain 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Breast cancer, early HER2+ (adjuvant treatment): </b>IV: 840 mg over 60 minutes followed by a maintenance dose of 420 mg over 30 to 60 minutes every 3 weeks for a total of 1 year (up to 18 cycles) or until disease progression or unacceptable toxicity (whichever occurs first); as part of a combination regimen containing trastuzumab and including standard anthracycline- and/or taxane-based therapy; pertuzumab and trastuzumab should begin on day 1 of the first taxane-containing cycle (von Minckwitz 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Breast cancer, early HER2+ (neoadjuvant treatment): </b> IV: 840 mg over 60 minutes followed by a maintenance dose of 420 mg over 30 to 60 minutes every 3 weeks for 3 to 6 cycles; may be administered as one of the regimens below. Postoperatively, continue trastuzumab to complete 1 year of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Four preoperative cycles of pertuzumab, trastuzumab, and docetaxel, followed by 3 postoperative cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) (Gianni 2012) <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Three or four preoperative cycles of FEC (alone) followed by 3 or 4 preoperative cycles of pertuzumab, trastuzumab, and docetaxel (Schneeweiss 2013) <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Six preoperative cycles of pertuzumab, trastuzumab, docetaxel, and carboplatin (Schneeweiss 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Four preoperative cycles of dose-dense doxorubicin and cyclophosphamide alone, followed by 4 preoperative cycles of pertuzumab, trastuzumab, and paclitaxel (Swain 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Missed doses or delays:</i> If &lt;6 weeks has elapsed, administer the 420 mg maintenance dose; do not wait until the next planned dose. If &ge;6 weeks has elapsed, readminister the 840 mg initial dose (over 60 minutes), and then follow with a maintenance dose of 420 mg (over 30 to 60 minutes) every 3 weeks.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472493\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472486\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &ge;30 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472487\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472485\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dose reductions are not recommended for pertuzumab; if trastuzumab is withheld, pertuzumab should also be withheld; if trastuzumab is discontinued, pertuzumab should be discontinued.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Infusion-related reaction:</i> Slow or interrupt the infusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Serious hypersensitivity or anaphylaxis:</i> Discontinue immediately</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Cardiotoxicity: </i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Metastatic breast cancer: Pretreatment left ventricular ejection fraction (LVEF) should be &ge;50%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">LVEF decline to &lt;40% <b>or</b> LVEF 40% to 45% with fall of &ge;10% points below pretreatment values: Withhold treatment (pertuzumab and trastuzumab) for at least 3 weeks; may resume if LVEF either returns to &gt;45% <b>or</b> to 40% to 45% with fall of &lt;10% points below pretreatment values. If LVEF declines and has not improved, or has declined further at the subsequent assessment, strongly consider discontinuing pertuzumab (and trastuzumab).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Early breast cancer: Pretreatment LVEF should be &ge;55%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">LVEF decline to &lt;50% with fall of &ge;10% points below pretreatment values: Withhold treatment (pertuzumab and trastuzumab) for at least 3 weeks; may resume if LVEF either returns to &ge;50% <b>or</b> &lt;10% points below pretreatment values. If LVEF declines and has not improved, or has declined further at the subsequent assessment, strongly consider discontinuing pertuzumab (and trastuzumab).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14476880\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Perjeta: 420 mg/14 mL (14 mL) [contains mouse (murine) and/or hamster protein]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14471961\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472494\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: For IV infusion only, as a short infusion; infuse initial dose (840 mg) over 60 minutes; infuse maintenance dose (420 mg) over 30 to 60 minutes. Do not administer IV push or as a rapid bolus. Do not mix with other medications. For pertuzumab, trastuzumab, and taxane combination regimens, pertuzumab and trastuzumab may be administered in any order; however, the taxane should be given after pertuzumab and trastuzumab. Pertuzumab (and trastuzumab) should be administered following completion of the anthracycline therapy in patients receiving anthracycline-based regimens. Observe patients for 30 to 60 minutes after each pertuzumab infusion and before subsequent infusions of trastuzumab or docetaxel.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132753\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14448338\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Breast cancer, metastatic:</b> Treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (in combination with trastuzumab and docetaxel) in patients who have not received prior anti-HER2 therapy or chemotherapy to treat metastatic disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Breast cancer, early (adjuvant):</b> Adjuvant treatment of HER2-positive early breast cancer at high risk of recurrence (in combination with trastuzumab and chemotherapy).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Breast cancer, early (neoadjuvant):</b> Neoadjuvant treatment of locally advanced, inflammatory, or early stage HER2-positive, breast cancer (either greater than 2 cm in diameter or node positive) in combination with trastuzumab and chemotherapy (as part of a complete treatment regimen for early breast cancer).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14471960\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pertuzumab may be confused with ado-trastuzumab emtansine, panitumumab, trastuzumab</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14477671\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Reactions reported in combination therapy with trastuzumab and docetaxel unless otherwise noted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (26% to 38%), headache (11% to 21%), decreased left ventricular ejection fraction (8% to 16%), insomnia (8% to 13%), dizziness (3% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia (52% to 65%), skin rash (11% to 34%; grades 3/4: &lt;1%), pruritus (4% to 14%), palmar-plantar erythrodysesthesia (11%), xeroderma (9% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (46% to 67%; grades 3/4: 5% to 8%), nausea (39% to 53%; monotherapy 24%), vomiting (13% to 36%; monotherapy 15%), decreased appetite (11% to 29%), constipation (23%), mucositis (20% to 28%), stomatitis (17% to 19%), dysgeusia (13% to 18%), abdominal pain (monotherapy 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Neutropenia (47% to 53%; grades 3/4: 43% to 49%), anemia (3% to 23%; grades 3/4: 3% to 4%), leukopenia (9% to 16%; grades 3/4: 5% to 12%), febrile neutropenia (8% to 14%; grades 3/4: 9% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity (1% to 11%; grades 3/4: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (15% to 26%), myalgia (11% to 23%), arthralgia (10% to 12%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (4% to 17%; grades 3/4: &lt;1%), epistaxis (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (9% to 19%; grades 3/4: 1%), infusion reactions (13%; grades 3/4: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Left ventricular dysfunction (3% to 4%), peripheral edema (3% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Peripheral sensory neuropathy (8%; grades 3/4: 1%), peripheral neuropathy (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Nail disease (7%), paronychia (1% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dyspepsia (8%), anorexia (monotherapy 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Thrombocytopenia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Increased lacrimation (4% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (5% to 8%), nasopharyngitis (7%), oropharyngeal pain (7%), cough (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports with combination therapy: Heart failure, pleural effusion, sepsis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472471\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Known hypersensitivity to pertuzumab or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472472\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiotoxicity: <b>[US Boxed Warning]: May result in cardiac failure (clinical and subclinical) manifesting as decreased left ventricular ejection fraction (LVEF) and heart failure (HF). Assess cardiac function at baseline and at regular intervals during treatment. Discontinue for confirmed clinically significant decline in left ventricular function. </b>Decreases in LVEF are associated with HER2 inhibitors, including pertuzumab. Patients who received prior anthracycline therapy or chest irradiation may be at an increased risk for cardiotoxicity. In studies of pertuzumab (versus placebo) in combination with trastuzumab and docetaxel for the treatment of metastatic breast cancer, the rate of cardiotoxicity (LVEF decline or symptomatic LV systolic dysfunction) was not increased in the pertuzumab group when compared to placebo. In the early breast cancer neoadjuvant setting, the incidence of LV dysfunction was higher in patients treated with pertuzumab. In the early breast cancer adjuvant setting, the incidence of symptomatic heart failure was slightly higher in patients treated with pertuzumab (most of these events were reported in anthracycline-treated patients); approximately half of the pertuzumab-treated patients who experienced symptomatic heart failure recovered. Of note, patients with pretreatment LVEF &le;50%, CHF, LVEF decreases to &lt;50% during prior trastuzumab treatment, or conditions which could impair LV function (eg, uncontrolled hypertension, recent MI, serious arrhythmia requiring treatment, or cumulative lifetime anthracycline exposure &gt;360 mg/m<sup>2</sup> doxorubicin or its equivalent) were excluded from studies. Assess LVEF at baseline and approximately every 12 weeks during treatment. Withhold pertuzumab and trastuzumab for at least 3 weeks if LVEF declines below the threshold for metastatic or early breast cancer; repeat LVEF assessment in ~3 weeks; consider discontinuing pertuzumab (and trastuzumab) if LVEF has not improved or has declined further.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal adverse events: Diarrhea occurred more frequently in patients receiving pertuzumab in combination with trastuzumab and docetaxel, compared to patients receiving only trastuzumab and docetaxel.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity/infusion reaction: Infusion reactions (either during or on the day of infusion) have been associated with pertuzumab; commonly described as fever, chills, fatigue, headache, weakness, myalgia, hypersensitivity, abnormal taste or vomiting. Grade 3 or 4 infusion reactions occurred rarely. The incidence of hypersensitivity/anaphylaxis was slightly higher in the group receiving pertuzumab (compared to placebo) in combination with trastuzumab and docetaxel. Monitor for 1 hour after the first infusion and for 30 minutes after subsequent infusions. For significant infusion reactions, interrupt or slow infusion rate; for severe infusion reactions, consider permanently discontinuing. Medications and equipment for the treatment of hypersensitivity should be available for immediate use during infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concomitant drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chemotherapy administration: For pertuzumab, trastuzumab, and taxane combination regimens, pertuzumab and trastuzumab may be administered in any order; however, the taxane should be given after pertuzumab and trastuzumab. Pertuzumab and trastuzumab should be administered following completion of the anthracycline therapy in patients receiving anthracycline-based regimens.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy:<b> [US Boxed Warning]: Pertuzumab exposure during pregnancy may result in embryo-fetal mortality and birth defects. Advise patients of the risks and the need for effective contraception.</b> Verify pregnancy status prior to treatment initiation. Effective contraception should be used by all patients receiving pertuzumab during therapy and for 7 months after the last dose (of pertuzumab in combination with trastuzumab) for women of childbearing potential.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; HER2 expression: Establish HER2 status prior to treatment. Improper assay performance (including suboptimally fixed tissue, failure to use specified reagents, deviation from assay instructions, and failure to include appropriate assay controls) may lead to unreliable results. Information on tests is available at <a target=\"_blank\" href=\"http://www.fda.gov/CompanionDiagnostics&amp;token=SHauxSdf9qNc6lLK16E8IPc+kYYsON95PtA1EteUbfjUoJYJ+uveJw2PtFUTXMkK&amp;TOPIC_ID=85639\" target=\"_blank\">http://www.fda.gov/CompanionDiagnostics</a>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14471029\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14471027\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=85639&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14471964\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">\n      <b>[US Boxed Warning]: Pertuzumab exposure during pregnancy may result in embryo-fetal mortality and birth defects. Advise patients of the risks and the need for effective contraception.</b> Verify pregnancy status prior to treatment initiation (in women of reproductive potential). Based on the mechanism of action of pertuzumab and data from similar agents, oligohydramnios or oligohydramnios sequence may occur resulting in pulmonary hypoplasia, skeletal anomalies, and neonatal death. Monitor for oligohydramnios if exposure occurs during pregnancy or within 7 months prior to conception; conduct appropriate fetal testing if oligohydramnios occurs. Effective contraception should be used during therapy and for 7 months after the last dose (of pertuzumab in combination with trastuzumab) for women of childbearing potential. Advise patients to immediately report to healthcare provider if pregnancy is suspected during treatment. If pertuzumab exposure occurs during pregnancy or exposure to pertuzumab in combination with trastuzumab occurs within 7 months prior to conception, healthcare providers should report the exposure to the Genentech Adverse Event Line (888-835-2555).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Women exposed to pertuzumab during pregnancy or exposed to pertuzumab in combination with trastuzumab within 7 months prior to conception are encouraged to enroll in MotHER Pregnancy Registry (1-800-690-6720 or www.motherpregnancyregistry.com).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">European Society for Medical Oncology (ESMO) guidelines for cancer during pregnancy recommend delaying treatment with HER2-targeted agents until after delivery in pregnant patients with HER2-positive disease (Peccatori 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14471966\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if pertuzumab is present in human milk. Because many immunoglobulins are excreted in human milk, and the potential for serious adverse reactions in the breastfed infant exists, the decision to discontinue breastfeeding or to discontinue pertuzumab should take into account the benefits of treatment to the mother. The extended half-life of pertuzumab and the 7-month wash out period for trastuzumab should be considered for decisions regarding breastfeeding after treatment is completed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472498\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">HER2 expression; pregnancy test; assess LVEF at baseline, and approximately every 12 weeks during treatment (more frequently for declines; monitor for infusion reaction and hypersensitivity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472479\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Pertuzumab is a recombinant humanized monoclonal antibody which targets the extracellular human epidermal growth factor receptor 2 protein (HER2) dimerization domain. Inhibits HER2 dimerization and blocks HER downstream signaling halting cell growth and initiating apoptosis. Pertuzumab binds to a different HER2 epitope than trastuzumab so that when pertuzumab is combined with trastuzumab, a more complete inhibition of HER2 signaling occurs (Baselga 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472481\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 5.12 L (Gianni 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Terminal: 18 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570440\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Perjeta Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">420 mg/14 mL (14 mL): $5,839.87</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22059505\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Per'Yeta (UA);</li>\n      <li>Perjeta (AR, AT, AU, BB, BR, CH, CR, CU, CY, CZ, DE, DK, DO, EE, ES, FR, GB, GT, HK, HN, HR, HU, IE, IL, IS, JP, KR, LB, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PH, PL, PT, QA, RO, SA, SE, SG, SI, SK, SV, TH, TR, VN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Agus DB, Gordon MS, Taylor C, et al, &ldquo;Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer,&rdquo; <i>J Clin Oncol</i>, 2005, 23(11):2534-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pertuzumab-drug-information/abstract-text/15699478/pubmed\" target=\"_blank\" id=\"15699478\">15699478</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baselga J, Cort&eacute;s J, Kim SB, et al, &ldquo;Pertuzumab Plus Trastuzumab Plus Docetaxel for Metastatic Breast Cancer,&rdquo; <i>N Engl J Med</i>, 2012, 366(2):109-19.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pertuzumab-drug-information/abstract-text/22149875/pubmed\" target=\"_blank\" id=\"22149875\">22149875</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baselga J, Gelmon KA, Verma S, et al, &ldquo;Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy,&rdquo; <i>J Clin Oncol</i>, 2010, 28(7):1138-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pertuzumab-drug-information/abstract-text/20124182/pubmed\" target=\"_blank\" id=\"20124182\">20124182</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baselga J and Swain SM, &ldquo;CLEOPATRA: A Phase III Evaluation of Pertuzumab and Trastuzumab for HER2-Positive Metastatic Breast Cancer,&rdquo; <i>Clin Breast Cancer</i>, 2010, 10(6):489-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pertuzumab-drug-information/abstract-text/21147694/pubmed\" target=\"_blank\" id=\"21147694\">21147694</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23969513\"></a>Cort&eacute;s J, Swain SM, Kudaba I, et al. Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel. <i>Anticancer Drugs</i>. 2013;24(10):1084-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pertuzumab-drug-information/abstract-text/23969513/pubmed\" target=\"_blank\" id=\"23969513\">23969513</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23999693\"></a>Garg A, Li J, Clark E, et al. Exposure-response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters. <i>Cancer Chemother Pharmacol</i>. 2013; 72(5):1133-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pertuzumab-drug-information/abstract-text/23999693/pubmed\" target=\"_blank\" id=\"23999693\">23999693</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gianni L, Llad&oacute; A, Bianchi G, et al, &ldquo;Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer,&rdquo; <i>J Clin Oncol</i>, 2010, 28(7):1131-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pertuzumab-drug-information/abstract-text/20124183/pubmed\" target=\"_blank\" id=\"20124183\">20124183</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gianni L, Pienkowski T, Im YH, et al, &ldquo;Efficacy and Safety of Neoadjuvant Pertuzumab and Trastuzumab in Women With Locally Advanced, Inflammatory, or Early HER2-Positive Breast Cancer (Neosphere): A Randomised Multicentre, Open-Label, Phase 2 Trial,&rdquo; <i>Lancet Oncol</i>, 2012, 13(1):25-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pertuzumab-drug-information/abstract-text/22153890/pubmed\" target=\"_blank\" id=\"22153890\">22153890</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24799465\"></a>Giordano SH, Temin S, Kirshner JJ, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.<i>J Clin Oncol</i>. 2014;32(19):2078-99.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pertuzumab-drug-information/abstract-text/24799465/pubmed\" target=\"_blank\" id=\"24799465\">24799465</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24129974\"></a>Miles D, Baselga J, Amadori D, et al. Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). <i>Breast Cancer Res Treat</i>. 2013;142(1):89-99.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pertuzumab-drug-information/abstract-text/24129974/pubmed\" target=\"_blank\" id=\"24129974\">24129974</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peccatori FA, Azim HA Jr, Orecchia R, et al; ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24(suppl 6):vi160-vi170.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pertuzumab-drug-information/abstract-text/23813932/pubmed\" target=\"_blank\" id=\"23813932\">23813932</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perjeta (pertuzumab) [prescribing information]. South San Francisco, CA: Genentech Inc; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perjeta (pertuzumab) [product monograph]. Mississauga, Ontario, Canada: Hoffmann-La Roche; February 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Portera CC, Walshe JM, Rosing DR, et al, &ldquo;Cardiac Toxicity and Efficacy of Trastuzumab Combined With Pertuzumab in Patients With [Corrected] Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer,&rdquo; <i>Clin Cancer Res</i>, 2008, 14(9):2710-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pertuzumab-drug-information/abstract-text/18451236/pubmed\" target=\"_blank\" id=\"18451236\">18451236</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24799487\"></a>Ramakrishna N, Temin S, Chandarlapaty S, et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2014;32(19):2078-99.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pertuzumab-drug-information/abstract-text/24799487/pubmed\" target=\"_blank\" id=\"24799487\">24799487</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schneeweiss A, Chia, S, Hickish, T, et al, &ldquo;Pertuzumab Plus Trastuzumab in Combination With Standard Neoadjuvant Anthracycline-Containing and Anthracycline-Free Chemotherapy Regimens in Patients With HER2-Positive Early Breast Cancer: A Randomized Phase II Cardiac Safety Study (TRYPHAENA),&rdquo; <i>Ann Oncol</i>, 2013;24(9):2278-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pertuzumab-drug-information/abstract-text/23704196/pubmed\" target=\"_blank\" id=\"23704196\">23704196</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Swain SM, Baselga J, Kim SB, et al; CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. <i>N Engl J Med</i>. 2015;372(8):724-734.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pertuzumab-drug-information/abstract-text/25693012/pubmed\" target=\"_blank\" id=\"25693012\">25693012</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23475636\"></a>Swain SM, Ewer MS, Cort&eacute;s J, et al. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. <i>Oncologist</i>. 2013;18(3):257-264.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pertuzumab-drug-information/abstract-text/23475636/pubmed\" target=\"_blank\" id=\"23475636\">23475636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"29253081\"></a>Swain SM, Ewer MS, Viale G, et al. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study [published online ahead of print December 15, 2017]. <i>Ann Oncol</i>. 2017. doi: 10.1093/annonc/mdx773.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pertuzumab-drug-information/abstract-text/29253081/pubmed\" target=\"_blank\" id=\"29253081\">29253081</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Swain SM, Kim SB, Cort&eacute;s J, et al, &ldquo;Pertuzumab, Trastuzumab, and Docetaxel for HER2-Positive Metastatic Breast Cancer (CLEOPATRA Study): Overall Survival Results from a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study,&rdquo; <i>Lancet Oncol</i>, 2013;14(6):461-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pertuzumab-drug-information/abstract-text/23602601/pubmed\" target=\"_blank\" id=\"23602601\">23602601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 3, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28581356\"></a>von Minckwitz G, Procter M, de Azambuja E, et al; APHINITY Steering Committee and Investigators. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer [published correction appears in: <i>N Engl J Med</i>. 2017;377(7):702.]. <i>N Engl J Med</i>. 2017;377(2):122-131. doi: 10.1056/NEJMoa1703643.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pertuzumab-drug-information/abstract-text/28581356/pubmed\" target=\"_blank\" id=\"28581356\">28581356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24101045\"></a>Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. <i>J Clin Oncol</i>. 2013;31(31):3997-4013.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pertuzumab-drug-information/abstract-text/24101045/pubmed\" target=\"_blank\" id=\"24101045\">24101045</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 85639 Version 111.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F14471959\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F14476879\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F21099907\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F14448325\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F14472492\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F14472493\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F14472486\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F14472487\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F14472485\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F14476880\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F14471961\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F14472494\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132753\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F14448338\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F14471960\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F14477671\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F14472471\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F14472472\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F14471029\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F14471027\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F14471964\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F14471966\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F14472498\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F14472479\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F14472481\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16570440\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F22059505\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/85639|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pertuzumab-patient-drug-information\" class=\"drug drug_patient\">Pertuzumab: Patient drug information</a></li></ul></div></div>","javascript":null}